-

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025.

Management will be available for one-on-one meetings with investors to discuss the company’s strategy, recent developments and future outlook in greater detail.

Presentation Details:

Date & Time: June 4, 2025, 12:50 PM Eastern Time

Location: New York City, NY

About DM199 (rinvecalinase alfa)

DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta. In the treatment of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibition of apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedica’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Release Versions

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

More News From DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia. The study achieved pre-specified safety and efficacy endpoints for the Part 1a dose escalation phase, reinforcing the therapeutic potential of DM199. DM199, rinvecalinase alfa, is a recombinant form of the KLK1 protein expected to influence blood pressure regula...

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investa...

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study. The webinar will feature Prof. Stephen Ton...
Back to Newsroom